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ABSTRACT
Introduction: To assess the efficacy and safety
of three available rapid-acting insulin analogs
(insulins lispro, aspart and glulisine, respec-
tively) in pregnant women, children/adoles-
cents and people using continuous
subcutaneous insulin infusion (CSII) with type
1 diabetes.
Methods: PubMed, EMBASE and Cochrane
Reviews were searched electronically, and their
bibliographies examined to identify
suitable studies for review and inclusion in a
meta-analysis. Eligible studies were randomized
controlled trials that reported data on relevant
clinical outcomes. A different reviewer abstrac-
ted data for each of the three subpopulations,
and one reviewer abstracted data for all three.
Any differences were resolved by consensus or
by consulting a fourth reviewer.
Results: In people on CSII, rapid-acting insulin
analogs lowered postprandial plasma glucose
post-breakfast to a greater extent than did reg-
ular human insulin (RHI) (mean difference:
- 1.63 mmol/L [95% confidence interval
- 1.71; - 1.54]), with a comparable risk of
hypoglycemia and a trend for lower glycated
hemoglobin. In the pediatric population, gly-
cemic control was similar with rapid-acting
insulin analogs and RHI, with no safety con-
cerns. Meta-analysis indicated severe hypo-
glycemic events were comparable for rapid-
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acting insulin analogs versus RHI (risk differ-
ence: 0.00 [95% confidence interval - 0.01;
0.01]). In the pregnancy group, insulin lispro
and insulin aspart were safe and effective for
both mother and fetus, with glycemic control
being at least as good as with RHI. There were
no data on insulin glulisine during pregnancy.
Conclusion: Rapid-acting insulin analogs
appear generally safe and effective in these
special populations; however, additional trials
would be helpful.
Funding: Novo Nordisk A/S.
Keywords: CSII; Pediatrics; Pregnancy; Rapid-
acting insulin analogs; Type 1 diabetes
INTRODUCTION
Many people with type 1 diabetes (T1D) receive
insulin therapy [1]. Rapid-acting insulins are
typically used to control postprandial plasma
glucose (PPG) excursions, whereas long-acting
basal insulins are used to control fasting glu-
cose. Rapid-acting insulins are used as part of a
basal–bolus injection regimen as well as for
continuous subcutaneous insulin infusion
(CSII). Three rapid-acting insulin analogs
(RAIAs) are currently available in the USA and
Europe: insulin lispro (Humalog; Eli Lilly,
Indianapolis, IN, USA), insulin aspart
(Novolog in the USA and NovoRapid in the
EU; Novo Nordisk, Bagsværd, Denmark) and
insulin glulisine (Apidra; Sanofi Aventis,
Bridgewater, NJ, USA). All three of these RAIAs
are also approved for the pediatric T1D patient
population, although the ages on the product
inserts for which there are data vary by product
as well as by country (e.g. USA: insulin lispro,
children C 3 years of age; insulin aspart,
C 2 years; insulin glulisine, C 4 years [2–4]; EU:
insulin lispro, age not specified; insulin aspart,
C 1 years; insulin glulisine, C 6 years) [5–7]. In
addition, despite the concerns in some coun-
tries, the use of RAIAs is very high in T1D
patients in general and is almost 100% among
those patients using CSII [8].
The three insulin analogs lispro, aspart and
glulisine differ in how their molecular structure
has been modified from human insulin [9] and
in the chemical composition of their formula-
tions [10], but their pharmacokinetic (PK) and
pharmacodynamic (PD) profiles are similar
(Electronic Supplementary Material [ESM]
Table S1). A large body of clinical studies indi-
cates that these three RAIAs have similar effi-
cacy and safety [11] and that they are preferred
over regular human insulin (RHI) for use in
adults with T1D due to their lower risk of
hypoglycemia [12].
However, certain subgroups of patients with
T1D (e.g. children and adolescents, pregnant
women and people using CSII) are typically
excluded from trials conducted for regulatory
approval to ensure a more homogeneous group
of patients.
A consequence of excluding these patients
from regulatory trials is that there is some
uncertainty about the clinical profile of RAIAs
in patients who may have unique metabolic,
developmental, cognitive or behavioral issues
that materially affect the suitability of any
medication. With RAIAs in widespread clinical
use, it is timely to examine the available evi-
dence for their performance in special popula-
tions. Thus, we performed a systematic review
and meta-analysis of published data (PROSPERO
registration #CRD42016043006).
METHODS
Sources of Data and Search Criteria
The search terms ‘‘insulin lispro’’ (MeSH Terms)
OR ‘‘insulin’’ (All Fields) AND ‘‘lispro’’ (All
Fields) OR ‘‘insulin lispro’’ (All Fields) OR ‘‘lis-
pro’’ (All Fields) OR aspart (All Fields) OR gluli-
sine (All Fields) were used to search the PubMed,
EMBASE and the Cochrane Reviews databases
electronically on 1 June 2016 to identify records
for further examination. The titles and abstracts
(and, when necessary, full papers) were then
screened to identify papers potentially report-
ing relevant in vivo data on safety or efficacy in
randomized controlled trials (RCTs) involving
one of three special populations (children and
adolescents with T1D; pregnant women with
pre-gestational T1D or gestational diabetes
[GDM]; people with T1D using CSII). We did
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not set a date range and therefore included any
study published up to the date of the search.
Reference lists of retrieved publications and
targeted review articles of RAIAs were also
searched to identify additional records that
might be provisionally relevant.
Selection of Studies and Eligibility Criteria
Records identified as provisionally relevant were
then further examined for eligibility to verify
that they were indeed RCTs, either blinded or
open-label and of parallel or crossover design, in
one of the target special populations and that
they reported data on one of the identified
clinical outcomes of interest. Eligibility for the
three study populations was as follows: for the
pregnancy population, women with either pre-
gestational T1D or GDM; for the pediatric pop-
ulation, children or adolescents aged\18 years
with T1D; for the CSII population, people with
T1D of any age using an insulin pump.
The criterion for the treatment in eligible
studies was the administration of one of the
three RAIAs compared with either RHI or each
other; trials in which the effect of the RAIA
could not be isolated (as in basal–bolus trials in
which different basal insulins were used in each
arm) were excluded. We did not pre-specify a
minimum duration for the studies, although
very short-term (e.g. 1- to 2-day meal tests
designed to study PK/PD) were excluded. Out-
come measures of interest included glycated
hemoglobin (HbA1c), fasting blood glucose
(FBG) or plasma glucose, PPG after any or all of
the three main meals, hypoglycemia, hyper-
glycemia, diabetic ketoacidosis and/or pump/-
catheter occlusion and, for pregnancy, fetal
outcomes.
Data Extraction
A standardized data abstraction form was
adapted for use in this systematic review. A
different reviewer abstracted data for each of the
three subpopulations (KN, NS, SR) using the
inclusion and exclusion criteria, and one
reviewer abstracted data for all three of the
subpopulations. Any differences were resolved
by consensus or, if necessary, by consulting a
fourth reviewer (PS) not involved in the original
data abstraction process for that population. All
reviewers are qualified at a post-doctorate level.
Data Synthesis and Statistical Analysis
For each of the three populations, whenever
possible, we extracted data on glycemic control
(HbA1c at baseline and end of trial; percentage
of patients achieving HbA1c target[s] as speci-
fied in individual trials; 7- or 8-point self-
measured blood glucose [SMBG]); and safety
endpoints (e.g. severe, nocturnal, overall hypo-
glycemia; hyperglycemia/ketosis; fetal out-
comes). For completeness, we also extracted
other secondary endpoints if available. Each of
the retrieved studies was assessed for study
quality, including sample size, reporting of
methods, reporting of results and risk of bias.
Finally, using this information, we graded each
study according to the following scale (-, ?,
??), with - indicating poor quality, ? indi-
cating average quality and ?? indicating good
quality.
All authors reviewed the available outcomes
data for each eligible study and decided which
studies had efficacy and/or safety data that
would be suitable for data combination and
meta-analysis within each of the three special
populations. Suitability was determined by
authors’ assessment of comparability of the
outcomes assessed.
Meta-analysis was conducted using Review
Manager 5 (RevMan 5.3 [http://community.
cochrane.org/tools/review-production-tools/rev
man-5]) software for Cochrane Reviews. Two
different outcome measures were used for the
safety variables in the meta-analysis (namely
risk difference for severe and any hypoglycemic
episodes per month) and three outcome mea-
sures for the efficacy variables (namely mean
difference in fasting and postprandial blood
glucose [BG] and in HbA1c). All models were
run as random-effects models. Statistical
heterogeneity was calculated by using the I2
statistic, and publication bias was assessed by
using a funnel plot and the Egger’s test.
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Compliance with Ethics Statement
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
Our search of the PubMed, EMBASE and the
Cochrane Reviews databases resulted in the
identification of seven eligible studies in preg-
nancy, nine in pediatric patients and 13 in people
using CSII. Records were assessed to be ineligible
and thereby excluded from the systematic review
and meta-analysis for numerous reasons, includ-
ing the study not being a RCT (observational
studies, letters, case reports or review articles were
excluded); ineligible population; in vitro or ani-
mal studies; study dealt with one of the RAIAs in
mixture formulations; outcomes of interest were
not reported; PK/PD studies in which basal insu-
lins were the focus of the study; study primarily
addressing stability in pumps; health–economics
studies without efficacy or safety outcomes; paper
written in a language other than English; dupli-
cate record; or study not applicable to this review
for other reasons. A flow diagram showing the
number of retrieved, excluded and included
records is shown in Fig. 1. Prior to submission of
this manuscript (August 2017), PubMed and the
Cochrane Reviews were searched as previously
described and no additional studies that would
have been provisionally eligible were identified.
Pregnancy
Characteristics of the seven eligible studies in
pregnancy (two in pre-gestational T1D [13–15]
and four in GDM [16–19], with two reporting
different outcomes from the same population
Fig. 1 Flow diagram showing the number of retrieved, excluded and included records. The dagger () indicates that the
continuous subcutaneous insulin infusion (CSII) group included two pediatric CSII studies. The asterisk (*) indicates that
in the CSII meta-analyses, the number of studies included varied depending on the outcome assessed. MDI Multiple daily
injections, PD pharmacodynamics, PK pharmacokinetics, RCT randomized controlled trial
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and therefore described in a single row [13, 14]),
are summarized in ESM Table S2, and the results
of those studies are shown in Table 1. Most (4/6
trials) involved\50 participants. Study quality
assessment is shown in ESM Table S3. Three
studies were graded as -, two were graded
as ? and one was graded as ??.
Women with Pre-Existing T1D
Persson et al. compared treatment with insulin
lispro with RHI treatment in a group of 33
pregnant women with T1D and found that the
BG level was significantly lower after breakfast
(but not after other meals) with insulin lispro
(0.40 ± 3.20 vs. 1.81 ± 3.42 mmol/L; p\ 0.01)
[15] (Table 1). The 95% confidence interval (CI)
was not significantly different between treat-
ments, either at 24 weeks gestation or before
delivery. The incidence of severe hypoglycemia
was low (zero and two episodes for insulin lispro
and RHI, respectively) and there were no dif-
ferences in perinatal outcomes or neonatal
complications.
The largest trial was an international, paral-
lel-group trial enrolling 322 women with T1D
who at enrollment were pregnant
for B 10 weeks or planning to become preg-
nant. Women were randomized to either insu-
lin aspart or RHI, both in combination with
neutral protamine Hagedorn insulin as the basal
insulin [14]. HbA1c levels were comparable in
the two groups at the end of the second and
third trimesters (treatment difference, insulin
aspart–RHI: - 0.04% [95% CI - 0.18; 0.11],
- 0.4 mmol/mol [95% CI - 2.0; 1.2]; and
- 0.08% [95% CI - 0.23; 0.06], - 0.9 mmol/-
mol [95% CI - 2.5; 0.7], respectively). Mean
plasma glucose levels at 90 min post-breakfast
were significantly lower in those women
receiving insulin aspart arm than in those
receiving RHI (p = 0.044 and p = 0.001 for end
of first and third trimesters, respectively). The
mean PPG increment across all meals was lower
for the insulin aspart arm than for the RHI arm
at the end of the first and third trimesters (es-
timated treatment difference: –0.75 [95% CI
- 1.25; - 0.25], p = 0.003 and - 0.40 [95% CI
- 0.80; - 0.01], p = 0.044, respectively). The
risk of major hypoglycemic events was numer-
ically lower, but not significantly different, for
insulin aspart (rate ratio 0.72 [95% CI 0.36;
1.46]).
In a publication reporting additional data on
pregnancy outcomes by Mathiesen et al. [14],
Hod et al. [13] indicated that preterm delivery
occurred in 20.3 and 30.6% of pregnancies in
women receiving insulin aspart and RHI,
respectively (p = 0.053). Other secondary pub-
lications from these trials indicated that there
were 137 and 131 live births, 14 and 21 fetal
losses, and six and nine congenital malforma-
tions in these groups of women on insulin
aspart and RHI, respectively. Furthermore,
maternal and cord blood antibody levels for
both RHI and insulin aspart remained low for
both treatments and were similar at 36 weeks
gestation for the 97 women who participated in
the substudy [20]. In a secondary analysis of
data from the same trial, Lloyd et al. reported
that these benefits were attained without
increasing the cost of treatment compared to
RHI [21].
Women with GDM
The characteristics of four RCTs using RAIAs in
GDM are summarized in ESM Table S2 [16–19].
The results indicate that insulin lispro was at
least as effective as RHI and sometimes
demonstrated improved glycemic control (ESM
Table S2) [16, 17, 19]. Insulin aspart was asso-
ciated with significantly lower post-meal BG
compared with RHI [16, 18]. In the single trial
involving a head-to-head comparison of insulin
aspart and insulin lispro, mean 1-h post-break-
fast BG was similar for the two products
(6.75 ± 1.12 vs. 6.6 ± 1.05 mmol/L, respec-
tively) [16].
In Mecacci et al. [17], hypoglycemia was not
reported and, in another trial, there were no
hypoglycemic events reported for insulin
aspart, insulin lispro or RHI [16]. In a study of
women (n = 27) using insulin aspart or RHI, the
reported percentage of participants experienc-
ing symptomatic hypoglycemic events was
similar for both treatments (71 vs. 69%), but
more participants using insulin aspart reported
minor hypoglycemia (79 vs. 39%) [18]. In the
latter case, this was largely due to two partici-
pants being prone to hypoglycemia. Neonatal
898 Diabetes Ther (2018) 9:891–917
outcomes (weight, length, physical exam) were
good for both insulin aspart and RHI.
Meta-Analysis
The pregnancy studies were deemed to be too
heterogeneous or to lack relevant information
for meta-analysis of either efficacy or safety
outcomes for any of the three RAIAs.
Children and Adolescents
There were nine eligible studies involving
pediatric patients with T1D [22–30]. The char-
acteristics of these studies are presented in ESM
Table S4 and the results are shown in Table 2.
Three trials compared insulin aspart with RHI
[22, 23, 28], five compared insulin lispro with
RHI [24–27, 30] and one compared insulin lis-
pro with insulin glulisine [29]. Most (5/9;
55.5%) trials involved\ 50 participants. Study
quality assessment is shown in ESM Table S5.
Four studies were graded as -, two were graded
as ? and three were graded as ??. Trials using
RAIAs in CSII in children are discussed in the
section ‘‘Patients Treated with CSII’’.
Overall, glycemic control (either HbA1c or
PPG) with insulin lispro or insulin aspart was
equivalent to or better than that with RHI. This
was also true with respect to incidence of
hypoglycemic episodes or other adverse events.
There were no head-to-head trials comparing all
three RAIAs in pediatric participants. However,
a large (n = 572), open-label, parallel-group,
non-inferiority trial compared insulin glulisine
with insulin lispro [29]. Insulin glulisine was
demonstrated to be non-inferior to insulin lis-
pro (treatment difference in HbA1c: - 0.06%
[95% CI - 0.24; 0.12]; - 0.7 [95% CI - 2.6;
1.33] mmol/mol). More children achieved
American Diabetes Association (ADA) age-
specific HbA1c targets (at the time of the
study:\6 years, HbA1c[7.5 to%\ 8.5% [ 58
to \69 mmol/mol]; 6–12 years, HbA1c\8.0%
[\ 64 mmol/mol]; 13–17 years, HbA1c\7.5%
[\ 58 mmol/mol]; currently, the ADA recom-
mends HbA1c\ 7.5% [\58 mmol/mol] across
all pediatric age groups [1]) with insulin gluli-
sine than with insulin lispro (overall popula-
tion: 38.4 vs. 32.0% for insulin glulisine and
insulin lispro, respectively; p = 0.039). The fre-
quencies of hypoglycemic events and other
adverse events were similar.
Meta-Analysis
Data on glycemic control were deemed to be too
heterogeneous or to lack relevant information
for meta-analysis, but the data on severe hypo-
glycemic outcomes were able to be combined
from five studies (Fig. 2a). Overall, the number
of severe hypoglycemic events was low (total of
14), and a random-effects model using generic
inverse variance showed no difference in risk of
severe hypoglycemia with insulin analog treat-
ment, risk difference 0 (95% CI - 0.01; 0.01).
Funnel plots suggested that there was no pub-
lication bias (data not shown).
Patients Treated with CSII
The largest number of eligible studies (n = 13)
was identified for people using CSII [31–43], of
which two were carried out in pediatric popu-
lations [42, 43] (ESM Table S6). The results are
presented in Table 3, and the study quality
assessment is shown in ESM Table S7. Two
studies were graded as -, three were graded
as ? and seven were graded as ??. One of the
studies consisted of two substudies, one of
which was graded as ?, and the second was
graded as ?? due to the double-blind
component.
Eight studies compared an RAIA with RHI
and all involved insulin lispro [32, 34–38, 41],
with one being a pediatric trial [42]. All were
crossover trials of 1–4 months’ duration. All
indicated that insulin lispro was associated with
improved glycemic control (HbA1c) and an
incidence of hypoglycemic events that was
similar to or lower than RHI.
Three studies involved head-to-head com-
parisons of insulin lispro versus insulin aspart
[33, 39, 43], with an additional trial also com-
paring RHI [31]. The largest of the three trials
was a 16-week, open-label RCT in 298 subjects
with T1D aged 4–18 years [43] (ESM Table S6).
At 16 weeks, the HbA1c in subjects receiving
insulin aspart was deemed to be non-inferior to
the HbA1c in those receiving insulin lispro, and
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there were no significant differences in FBG or
rates of hyper- and hypoglycemia. However, the
daily insulin dose was significantly lower for
groups on insulin aspart (0.86 ± 0.237 vs.
0.94 ± 0.233 U/kg, for insulin aspart vs. insulin
lispro, respectively; p = 0.018) [43]. In two
related, 24-week, randomized, crossover trials in
adults with T1D, insulin lispro was assessed to
be non-inferior to insulin aspart based on SMBG
profiles averaged over days 1–6 of treatment,
but not when day 6 values alone were compared
[39]. In a randomized, parallel-group trial in 146
adults with T1D, mean change from baseline
was not significantly different for participants
treated with insulin lispro, insulin aspart or RHI
for 16 weeks [31]. Rates of hypoglycemia were
also similar among treatments.
One RCT compared all three RAIAs in adults
[40]. This was a crossover trial with three
13-week periods that was designed to test the
superiority of insulin glulisine for unexplained
hyperglycemia and/or infusion-set occlusion. It
failed to show superiority of insulin glulisine on
the primary outcome, but revealed that the
monthly rate of unexplained hyperglycemic
episodes and/or perceived catheter-set occlu-
sion was significantly higher in insulin gluli-
sine-treated patients than in those receiving the
two other analogs [40]. Furthermore, insulin
glulisine was associated with a higher frequency
of symptomatic hypoglycemia, whereas HbA1c
and 7-point SMBG were similar for all three
insulin analogs [40].
Meta-analysis
Data on mean FBG and mean PPG for patients
using CSII were sufficiently consistent to permit
some meta-analysis, as were some of the hypo-
glycemic outcomes. Funnel plots suggested that
there was no publication bias, although the
number of studies in the meta-analysis with
FBG outcomes was small (funnel plots not
shown). Meta-analysis was performed for RAIAs
versus RHI for FBG (three studies) (Fig. 2b), PPG
(five studies) (Fig. 2c), severe hypoglycemic
episodes (six studies) (Fig. 2d), any hypo-
glycemic episodes (five studies) (Fig. 2e) and
HbA1c (four studies) (Fig. 2f). A random-effects
model using generic inverse variance showed a
mean difference in FBG of - 0.53 mmol/L
bFig. 2 Meta-analyses of key outcomes. a Forest plot
showing the difference in risk of severe hypoglycemic
episodes with insulin analog treatment compared to regular
human insulin (RHI) in a pediatric population. b Forest
plot showing the difference in the mean fasting blood
glucose level with insulin analog treatment compared to
RHI treatment in the CSII sub-review. c Forest plot
showing the difference in mean postprandial blood glucose
(BG) level with insulin analog treatment compared to RHI
treatment in the CSII sub-review. d Forest plot showing
the difference in risk of severe hypoglycemic episodes with
insulin analog treatment compared to RHI treatment in
the CSII sub-review. e Forest plot showing the mean
difference in the rate of any hypoglycemic episodes with
insulin analog treatment compared to RHI treatment in
the CSII sub-review. f Forest plot showing the difference
in glycated hemogloblin (HbA1c) with insulin analog
treatment (lispro or aspart) compared to RHI in the CSII
sub-review.
Squares and diamonds represent the difference in HbA1c
after intervention with the two treatments for each study
(horizontal lines are 95% CI) and for all the studies
combined, respectively. The I2 value refers to the statistical
heterogeneity for the pooled analysis. A random-effects
model using generic inverse variance showed a mean
difference in HbA1c of - 0.19% (95% CI - 0.46; 0.08);
- 2.1 (95% CI - 5.0; 0.9) mmol/mol with insulin analog
compared to RHI at the end of the treatment period. The
squares and the diamond in a, d, e represent the difference
in risk for each study (horizontal lines represent 95% CI)
and for all studies combined, respectively. The squares and
the diamond in b, c represent the difference in the glucose
levels between the two treatment arms for each study
(horizontal lines are 95% CI) and for all the studies
combined, respectively. The results of these meta-analyses
are the mean of post-breakfast BG measurements only. In
a and d ‘Events’ refers to the number of patients
experiencing any such episode during the treatment period
as a proportion of total number of patients in that
treatment group. ‘Rate’ refers to mean (± SD) of any
episodes of hypoglycemia per 30 days in all the patients in
the respective treatment group. In f ‘Bode, 2002 (a)’ [31]
refers to the observed difference in HbA1c between the
subgroup of insulin lispro vs. RHI, and ‘Bode, 2002 (b)’
[31] refers to the subgroup on insulin aspart vs. RHI; the
three remaining studies compare lispro vs. RHI. The ‘I2’
value refers to the statistical heterogeneity for this pooled
analysis. CI conﬁdence interval, IV inverse variance,
SD standard deviation
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(95% CI - 1.21; 0.15), a mean difference for
PPG of – 1.63 mmol/L (95% CI - 1.71; –1.54), a
risk difference for severe hypoglycemic episodes
of - 0.01 (95% CI - 0.04; 0.02) and a mean
difference in rate of any hypoglycemic episode
of - 0.75 (95% CI - 2.21; 0.72). The mean dif-
ference in HbA1c was - 0.19% (95% CI - 0.46;
0.08); - 2.1 mmol/mol (95% CI - 5.0; 0.9) with
RAIAs compared to RHI after 3 or 4 months of
treatment.
DISCUSSION
This systematic review and meta-analysis sum-
marizes the safety and efficacy of RAIAs in
populations of patients who are either typically
excluded from clinical trials (i.e. due to preg-
nancy) or require dedicated trials (i.e. children
and adolescents, patients using CSII). Overall,
for insulin lispro and insulin aspart, data across
all three special populations indicate that their
safety and efficacy are comparable with, and in
some cases significantly better than, RHI. Data
also suggest, from the more limited results
available, similar characteristics for insulin
glulisine.
There are no head-to-head RCTs individually
comparing all three RAIAs with each other in
the pediatric CSII setting. However, in 2009, the
Institute for Quality and Efficiency in Health
Care in Germany, acknowledging the limited
amount of data at the time, concluded that
there were no significant differences between
RHI and any of the three RAIAs in terms of key
efficacy and safety endpoints [44]. The UK
National Institute for Health and Care Excel-
lence (NICE) guidelines specifically indicate
that RAIAs are preferred over RHI for use in CSII
for pediatric patients [45].
Given the lack of any major safety concerns
when the three RAIAs were studied individually,
there is no a priori reason to suspect that head-
to-head trials would reveal any substantive dif-
ferences in safety among them in special pop-
ulations. However, without randomized
comparative trials in these special populations,
that conclusion remains speculative. Due to the
limited number of studies and the heterogene-
ity of the outcome measures, only limited meta-
analysis was possible, primarily in the CSII
population. Those results indicate that RAIAs in
CSII lower post-breakfast BG and possibly
HbA1c to a greater extent than RHI, without an
increased risk of hypoglycemia. Although many
trials have been published using CSII versus
multiple daily injections (MDI) in pediatric
subjects, we did not review those here because it
was impossible to separate the effects of the
RAIA from those of the mode of treatment (CSII
or MDI).
CONCLUSIONS
Rapid-acting insulin analogs appear to be safe
and effective in these three special populations
of people with T1D. However, additional trials
would be helpful, and head-to-head trials would
be necessary to detect any statistical differences
among them, should they exist. The lack of
clinically relevant differences in performance
among the RAIAs make other factors, such as
cost, availability and patient/provider prefer-
ence, more important. Finally, studies have now
been published indicating the PK advantages of
a new formulation of insulin aspart in clinical
development (faster aspart) over conventional
insulin aspart [46], including in pediatric pop-
ulations [47] and in those using CSII [48].
Studies addressing the performance of new fast-
acting insulin aspart versus insulin glulisine and
insulin lispro in these special populations in a
clinical setting would be advantageous.
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